Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.53 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27656468 | 0.90 | TRPV1 (0.66) | PTPN1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1829494 | 0.85 | TRPV1 (0.60) | NPC1RAB9APOLBTDP1TRPV1 | |
| SCHEMBL27635480 | 0.84 | MEN1 (0.59) | PTPN1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1827871 | 0.82 | LMNA (0.51) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL23226706 | 0.81 | STING1 (0.75) | PTPN1MEN1KMT2APOLB | |
| SCHEMBL23226833 | 0.80 | TRPV1 (0.49) | NPC1RAB9AMEN1KMT2ATRPV1 | |
| SCHEMBL5964783 | 0.80 | ALDH1A1 (0.51) | NPC1RAB9APOLBTDP1TRPV1 | |
| SCHEMBL5944298 | 0.80 | HDAC6 (0.56) | — | |
| SCHEMBL1828384 | 0.80 | TRPV1 (0.60) | NPC1RAB9AMEN1KMT2ATRPV1 | |
| SCHEMBL30679727 | 0.79 | NR3C1 (0.52) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651232-B1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2010-12-22 | — | — | EP | claimed |
| EP-1651232-A4 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2007-06-06 | — | — | EP | claimed |
| EP-1653968-A4 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS CORP (US) | 2006-09-06 | — | — | EP | claimed |
| EP-1653968-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | Synta Pharmaceuticals Corporation (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1651232-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2006-05-03 | — | — | EP | claimed |
| US-20050148633-A1 | Calcium channel blockers and releasing ions for prodrugs | SYNTA PHARMACEUTICALS CORP. | 2005-07-07 | — | — | US | claimed |
| US-20050107436-A1 | phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2005-05-19 | — | — | US | claimed |
| WO-2005009954-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | claimed |
| WO-2005009539-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | claimed |
| WO-2023223738-A1 | METHOD FOR PRODUCING THERMOPLASTIC RESIN COMPOSITION, METHOD FOR DETERMINING MOLDABILITY OF THERMOPLASTIC RESIN COMPOSITION, AND THERMOPLASTIC RESIN COMPOSITION FOR MOLDING AT TEMPERATURE THAT IS NOT LESS THAN DECOMPOSITION TEMPERATURE OF ELASTOMER | ポリプラスチックス株式会社 | 2023-11-23 | — | — | WO | disclosed |
| WO-2019139061-A1 | PIPE-SHAPED INTEGRALLY MOLDED ARTICLE AND PRODUCTION METHOD FOR PIPE-SHAPED INTEGRALLY MOLDED ARTICLE | 東レ株式会社 | 2019-07-18 | — | — | WO | disclosed |
| WO-2015056393-A1 | POLYAMIDE RESIN COMPOSITION, MANUFACTURING METHOD, AND MOLDED ARTICLE | 東レ株式会社 | 2015-04-23 | — | — | WO | disclosed |
| WO-2015046324-A1 | POLYARYLENE SULFIDE RESIN COMPOSITION | 東レ株式会社 | 2015-04-02 | — | — | WO | disclosed |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20050148633-A1 | Calcium channel blockers and releasing ions for prodrugs | SYNTA PHARMACEUTICALS CORP. | 2005-07-07 | — | — | US | disclosed |
| US-20050107436-A1 | phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2005-05-19 | — | — | US | disclosed |
| WO-2005009954-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009954-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009539-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009539-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148633-A1 | Calcium channel blockers and releasing ions for prodrugs | ORAI1, CACNA1C, CACNA1F | PTPN1 2149/4885NPC1 337/4885RAB9A 841/4885 |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | PTPN1 438/4885NPC1 142/4885RAB9A 1725/4885 |
| US-20050107436-A1 | phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | TPMT, PTPN3, FKBP3 | PTPN1 11/4885NPC1 405/4885RAB9A 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.